Amgen (AMGN) Change in Intangibles (2014 - 2015)

Amgen (AMGN) recorded quarterly Change in Intangibles of $5.0 million in Q3 2015, down 96.3% quarter-over-quarter from $135.0 million in Q4 2014.

Amgen (AMGN) Change in Intangibles (2014 - 2015) Analysis & Trends

Amgen's Change in Intangibles history runs 2 years deep, the most recent figure standing at $5.0 million for Q3 2015.

In Q3 2015, Change in Intangibles changed N/A year-over-year to $5.0 million; the TTM figure through Dec 2015 stood at $140.0 million (changed N/A YoY), while the FY2016 annual figure was $99.0 million, up 80.0% from the prior year.
Change in Intangibles was $5.0 million for Q3 2015 at Amgen, down from $135.0 million in the prior quarter.
In the past five years, Change in Intangibles ranged from a high of $135.0 million in Q4 2014 to a low of $5.0 million in Q3 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Intangibles (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	-299.30 Mn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	-
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	-
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	-
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	-
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	-
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	-
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	-
10	Novartis Ag	108.28 Bn	107.60 Bn	-	-461.00 Mn

Download Data